Physician profile
Danielle Lonsway
NPI 1265080204
$1,674.40
in general payments reported to CMS, 2019-2025
10 companies · $297 in 2025
The $297 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $48.01 · 2023: $271 · 2024: $1,058 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,545 · Education: $81.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,544.90 |
| Education | $81.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $440.76 | 2024-2025 | Austedo Xr |
| Jazz Pharmaceuticals INC. | $373.25 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $199.42 | 2024 | Nuplazid |
| Boston Scientific Corporation | $143.90 | 2023 | Watchman Access System |
| Sk Life Science, INC. | $125.00 | 2025 | Xcopri |
| Neurocrine Biosciences, INC. | $124.99 | 2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $122.36 | 2024 | Rexulti |
| Neurelis, INC. | $82.28 | 2024 | Valtoco |
| Genentech USA, INC. | $48.01 | 2021 | |
| Ucb, INC. | $14.43 | 2024 | Fintepla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Lonsway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.